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The Cosmetics Europe (formerly COLIPA) Genotoxicity Task Force has driven and funded three projects to
help address the high rate of misleading positives in in vitro genotoxicity tests:
The completed ‘‘False Positives’’ project optimized current mammalian cell assays and showed that the
predictive capacity of the in vitro micronucleus assay was improved dramatically by selecting more rel-
evant cells and more sensitive toxicity measures.
The on-going ‘‘3D skin model’’ project has been developed and is now validating the use of human
reconstructed skin (RS) models in combination with the micronucleus (MN) and Comet assays. These
models better reﬂect the in use conditions of dermally applied products, such as cosmetics. Both assays
have demonstrated good inter- and intra-laboratory reproducibility and are entering validation stages.
The completed ‘‘Metabolism’’ project investigated enzyme capacities of human skin and RS models. The
RS models were shown to have comparable metabolic capacity to native human skin, conﬁrming their
usefulness for testing of compounds with dermal exposure.
The program has already helped to improve the initial test battery predictivity and the RS projects have
provided sound support for their use as a follow-up test in the assessment of the genotoxic hazard of cos-
metic ingredients in the absence of in vivo data.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The focus of many researchers has been to develop better
in vitro tools to replace animal tests, especially in the light of reg-
ulations such as the 7th amendment to the Cosmetics Directive
(EU, 2003) and REACh (European Commission, 2006). The use of
in vitro models is especially relevant to the cosmetics industry
which is banned from using animal tests for a number of end-
points, including genotoxicity. Thus, positive outcomes in standardin vitro assays evaluating the genotoxic potential of chemicals can
no longer be followed-up with in vivo assays. If genotoxicity is as-
sessed using only in vitro assays, this may well result the de-selec-
tion of many safe new products since these assays have a high rate
of positive results that do not correlate with in vivo genotoxicity or
carcinogenicity (Kirkland et al., 2005). This problem is recognized
as a critical issue and has led to a number of working groups inves-
tigating improved approaches for assessing genotoxicity (e.g.,
International Life Sciences Institute – Human and Environmental
Sciences Institute’s (ILSI-HESI) committee on The Relevance and
Follow-up of Positive Results in in vitro Genotoxicity Testing
(IVGT); www.hesiglobal.org). As part of an international and mul-
ti-laboratory collaboration, Cosmetics Europe (formerly ‘‘COLIPA’’)
has funded and driven numerous projects aimed to address the
lack of adequate alternatives to traditional in vivo tests and help
validate successful models.
Fig. 1. A comparison of the formation of MN in different cell types. Each cell type
was tested with solvent (h) and low ( ), medium ( ) and high (j) concentrations
of resorcinol for 3 h in the presence of S9. Resorcinol caused statistically signiﬁcant
increases (denoted as ‘‘’’) in MN formation in V79, CHL and CHO cells but not in
human lymphocytes (HuLy), TK6 cells or HepG2 cells. (Reproduced from Fowler
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coordinate and drive three main projects. The aim of the ‘‘False
Positives’’ project was to optimize current mammalian cell assays
by focusing on two aspects of the micronucleus (MN) test, namely
the cell type employed and the method of cytotoxicity measure-
ment. The ‘‘3D skin model’’ project aimed to develop and validate
a new assay incorporating the use of human reconstructed skin
(RS) models with the genotoxicity endpoints, MN and Comet as-
says. Since the exposure of many compounds is dermal, especially
for cosmetics, these models better reﬂect their in use conditions. In
order to interpret outcomes from the 3D model assays, knowledge
of the metabolic capacity of these RS models is an advantage, espe-
cially in comparison with native human skin. Therefore, the
‘‘Metabolism’’ project investigated the enzyme capacities of human
skin and compared them with that in RS models and with 2D
monolayer cultures of skin cells.
Here, we review the outcomes of the Genotoxicity Task Force
projects, outline future research aims and apply the knowledge
gained to a decision tree approach to assess the genotoxic potential
of chemicals used in the cosmetics industry.et al., 2012a).2. The ‘‘False Positives’’ project
One of the drawbacks of the current in vitro clastogenicity as-
says is that they produce many positive results when compared
with negative rodent carcinogenicity data. Indeed, an analysis of
published data revealed the rate of misleading positives to be at
least 80% when three in vitro assays were combined into a test bat-
tery (Kirkland et al., 2005), as requested by several guidelines (such
as Reach European Commission, 2006 and the SCCS notes of guid-
ance SCCP, 2009). Therefore, existing and new assays need to show
better speciﬁcity (i.e. correctly identify non-carcinogens) without
compromising sensitivity (i.e. still detecting in vivo genotoxins
and DNA-reactive carcinogens). The ‘‘False positive’’ project was
set up to optimize the in vitro MN test such that the methodology
described in the OECD guideline 487 (OECD, 2010) was retained.
A European Center for the Validation of AlternativeMethods (EC-
VAM) workshop held in 2006 discussed ways to reduce the fre-
quency of misleading positive results. Several suggestions for
possible improvements/modiﬁcations to existing tests were identi-
ﬁed, including the cell lines used and the method of cytotoxicity
measurement (Kirkland et al., 2007). Following from these recom-
mendations we started a program which was executed at Covance
Laboratories, UK,wherewe investigatedhowthepredictive capacity
of the in vitroMN test is impacted by the choice of cell lines (Fowler
et al., 2012a) and toxicity parameters (Fowler et al., 2012b). Others
have compared different cell types (Sofuni et al., 1990; Hilliard
et al., 2007; Erexson et al., 2001) but this is the ﬁrst comparison that
includes six cell types within the same project and using consistent,
GLP-like experimental conditions including the same batches of
chemicals, media and formulations (Fowler et al., 2012a). These
investigations revealed that certain cell types were more prone to
misleading positive responses than others, particularly rodent cell
lines (Fig. 1). The p53 compromised rodent cell lines, CHL, CHO
and V79, demonstrated poorer speciﬁcity than the p53 functional
human cell types, TK6, HepG2 and human peripheral blood lympho-
cytes (HuLy) in response to compounds accepted as producing mis-
leading positive results in in vitro clastogenicity assays (Kirkland
et al., 2008). Cells of human origin may also be more favorable than
rodent cells since these aremore representative of human responses
and may contain more human-speciﬁc metabolising enzymes and
transporter proteins than rodent-derived cell types. Improving
speciﬁcity cannot be at the expense of compromised sensitivity
and thus it was necessary to make sure that the choice of cells did
not lead to a decrease in sensitivity. Seventeen carcinogens thatare thought to act via genotoxic mechanism (from the Group 1
chemicals from Kirkland et al., 2008) were re-tested in human lym-
phocytes and TK6 cells. Overall the data show that out of a panel of
17genotoxic chemicals, TK6andHuLydetect themajorityof themas
positive (15 out of 17; 88% accuracy), conﬁrming the high sensitivity
of these cells (Fowler et al., 2013).
Investigations of the cell type employed the replication index
(RI) as a measure of cytotoxicity; however, it was considered that
cytotoxicity may also be a parameter that could inﬂuence the out-
come of the assay since this is used to select the top concentration
tested (Kirkland et al., 2007). For example, one study showed that
Relative Cell Counts (RCC) underestimated the toxicity of a number
of direct and indirect genotoxins and thus selected higher concen-
trations for subsequent MN analysis (Fellows et al., 2008). There-
fore, additional measures of cytotoxicity of a number of
misleading positives in CHO, CHL and TK6 cells were investigated
in the ‘‘False Positives’’ project, namely Relative Population Dou-
bling (RPD), Relative Increase in Cell Counts (RICC), RI and RCC. Re-
sults revealed that estimation of toxicity based on relative
proliferation increases (RPD and RICC) tended to select concentra-
tions in the target toxicity range (50–60%) that give mainly nega-
tive MN responses (Fig. 2). Conversely, measurements of RCC and
RI selected concentrations in the target toxicity range gave mainly
positive MN responses. Therefore, using RICC and RPD to select
concentrations for MN analysis reduces the number of misleading
positive results, regardless of cell type, by selecting lower concen-
trations for analysis than when RCC or RI are used. The use of RICC
and RPD does not result in a lower sensitivity of the assay. Others
have shown that when RPD and RICC were used as measures of
cytotoxicity of 14 known genotoxic agents, all selected concentra-
tions for MN analysis gave rise to expected positive responses in a
range of commonly used cell types (Kirkland, 2010). Another con-
sideration is the effect of apoptosis inducing chemicals, such as
curcumin and ethyl acrylate, which could contribute to the positive
MN responses. In p53-competent TK6 cells, concentrations se-
lected for MN analysis using the RCC and RI toxicity measures also
caused increased levels of caspase activity, suggesting apoptosis
had occurred. By contrast, when RPD and RICC were used to select
concentrations, caspase levels were not signiﬁcantly elevated, thus
apoptosis was avoided and MN frequencies were close to back-
ground levels (see Fowler et al., 2012b for more detail on all of
the results discussed above).
It was concluded that a combination of careful selection of the
cell type and toxicity measurement can signiﬁcantly increase the
Fig. 2. Concentrations of misleading positive compounds resulting in 50–60%
toxicity in TK6 cells according to different measurements. RPD and RICC tended to
result in lower concentrations causing 50–60% toxicity and subsequently, fewer
misleading positive responses. Bars with ‘‘+ve MN’’ indicate that the concentration
indicated caused a statistically signiﬁcant increase in MN formation (Reproduced
from Fowler et al., 2012b).
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IWGT workshop reviewed by Pfuhler et al., 2011). The now com-
pleted ‘‘False Positives’’ project has undoubtedly lead to an
improvement in the predictive capacity of the in vitro MNT. The
higher predictive power of the in vitro assays will mean that fewer
promising chemicals will be dropped from development without
compromising safety of these ingredients.Table 1
Summary of the validation of the RS Comet and RSMN assays.
RSMN assay RS Comet assay
Phase
1
Completed: Optimization of
incubation conditions. Correct
prediction of 5 dermal non-
carcinogens and 7 model
genotoxins including genotoxic
dermal carcinogens
Completed: Assay readily
adapted and transferred to
different laboratories. Good
intra- and inter-laboratory
reproducibility with 2 model
genotoxins
Phase
2
Completed: Transfer to different
laboratories. Good intra- and
inter-laboratory reproducibility
of MN responses to 3 different
coded chemicals. Correct
identiﬁcation of positive and
negative genotoxicants
Completed: Good intra- and
inter-laboratory reproducibility
of responses to 5 different coded
chemicals. Correct identiﬁcation
of positive and negative
genotoxicants. Optimization of
RS model transport
Phase
3
On-going: Number of chemicals
tested increased to 29. Initial
results show improved
speciﬁcity of the RSMN assay.
Requires testing of additional
positive chemicals to conﬁrm
sensitivity of the assay
Not started. Project is merging
with a project sponsored by the
‘‘Bundesministerium für Bildung
und Forschung’’ (BMBF) to more
efﬁciently test the validation
chemicals3. The ‘‘3D skin model’’ project
The ﬁrst site of exposure tomany cosmetic ingredients is the skin
and, as a result, these chemicals may not enter the systemic circula-
tion due to the barrier properties of the stratum corneum, ormay be
metabolized in the skin prior to entering the systemic circulation.
Therefore, themost relevantmodel in which to test these chemicals
is human skin. However, the availability of fresh ex vivo human skin
is sporadic which, together with the donor variability and differ-
ences in tissue quality, makes the use of this model impractical for
routine testing. Alternatives to native human skin are RS models
which are prepared from primary human keratinocytes. These have
a structure (Ponec et al., 2001) and metabolic capacity (Luu-The
et al., 2009; Hu et al., 2010; Götz et al., 2012a,b; van Eijl et al.,
2012) similar to that of native skin, making RS models a relevant
and predictive model with which to test the genotoxic potential of
dermally exposed chemicals. Indeed, the use of RS models in geno-
toxicity risk assessment has been described recently (Pfuhler et al.,
2010). The in vitro human reconstructed skin micronucleus (RSMN)
and Comet assayswere developed for evaluating the genotoxicity ofdermally applied chemicals. The project has been run according to a
modular approach:
 Phase 1: Optimization and transferability of method across dif-
ferent laboratories.
 Phase 2: Inter- and intra-laboratory reproducibility.
 Phase 3: Increasing the domain of chemicals tested for predic-
tive capacity and further evaluation of reproducibility.
The two endpoints have so far produced very promising results,
as described below and summarized in Table 1.4. The reconstructed skin micronucleus (RSMN) assay
The in vitroMN assay was adopted for use with RS models to as-
sess the genotoxic potential of a number of chemicals selected by
an independent Chemical Selection Expert team, including positive
genotoxins with different mechanisms of action, true negatives
and misleading positives (Kirkland et al., 2008). The initial proto-
cols were deﬁned (Curren et al., 2006) and then tested in three
US laboratories (Mun et al., 2009; Hu et al., 2009). In Phase 1, the
RSMN assay method was transferred to Henkel and L’Oréal, both
European-based (Germany and France, respectively), which was
of signiﬁcance because the RS models were supplied from a US pro-
vider (MatTek, MA). As part of this process, two training workshops
were held to standardize the protocol and harmonize scoring of
micronuclei, both of which were subsequently described and pub-
lished by Dahl et al. (2011). The workshops outlined three key is-
sues impacting on the assay, namely the shipping (which should
be overnight and under cooled conditions); the solvents used
(avoid those that interfere with the air–liquid interface of the Epi-
Derm™ model); and the subjective nature of the scorer (solved by
creating a scoring atlas described by Dahl et al., 2011).
InPhase2, three codedcompounds (N-ethyl-N-nitrosourea (ENU),
MMC (both genotoxic carcinogens) and cyclohexanone (non-carcino-
gen and non-genotoxic)) were tested by three laboratories (Aardema
et al., 2010). In addition to a good reproducibility between experi-
ments within each laboratory, there was also a good inter-laboratory
reproducibility for all threechemicals tested.Moreover, thegenotoxic
activity of each chemical was correctly identiﬁed in each laboratory.
In Phase 3, the number of coded chemicals was increased to 29
as part of the validation process. All results were sent to ECVAM for
decoding and evaluation according to speciﬁc pre-determined
criteria. Results demonstrated an excellent speciﬁcity such that
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toxic non-carcinogens correctly (Fautz et al., 2012). Of the 29
chemicals tested, only 8 chemicals were classiﬁed as carcinogens
with a suggested genotoxic mode of action and 21 were non-car-
cinogens. Therefore, the current dataset is biased towards non-car-
cinogens with the total number of carcinogens in the dataset
considered too low to draw a ﬁnal conclusion about the sensitivity
of the RSMN assay. More coded compounds will be tested in the
next project phase with a focus on carcinogens.
During the testing, it was noted that a couple of compounds
precipitated, which was not considered in the initial criteria, but
should be included in future evaluations. A misleading negative
may arise if the intended concentration is not reached or false pos-
itives can be caused by precipitation due to practical issues such as
difﬁculties in scoring (especially with compounds that ﬂuoresce at
the same wavelengths as acridine orange) or disruption of the air-
liquid interface which can cause MN formation (Dahl et al., 2011).
In order to speed up the scoring of the MN, efforts towards auto-
mation are on the way. This should enable analysis of a greater
number of cells, resulting in a higher statistical power of the assay
and incorporate an automatic cytotoxicity measurement as part of
the analysis. Initial results show good comparisons between man-
ual scoring and ﬂow cytometric methods (unpublished data).
Some genotoxins require metabolic activation; therefore, we
have investigated a number of chemicals that fall into this cate-
gory, namely 4-nitroquinoline-n-oxide (4NQO), cyclophospha-
mide, dimethylbenzanthracene (DMBA), dimethylnitrosamine
(DMN), dibenzanthracene (DBA) and benzo[a]pyrene (BaP). Since
the skin has been shown to have a very low phase 1 (normally
bioactivating) capacity, it was considered that these chemicals
may require a longer incubation duration in order to generate
sufﬁcient levels of the ultimate genotoxin. However, extending
the dosing regimen from 48 h and two doses to 72 h and three
doses did not always change the outcome of the assay, such that
cyclophosphamide and DMBA were positive and DBA and DMN
were negative using both dosing regimen. The outcome of the as-
say was only changed for 4NQO, which was negative in the stan-
dard 48 h dosing regimen, but positive with the 72 h treatment
(Aardema et al., 2012). BaP gave mixed results, possibly due to
this chemical precipitating at high concentrations and to altera-
tions in metabolic enzyme levels caused by BaP (Götz et al.,
2012c). The results for DBA and DMN may be expected since,
for DBA, the level of CYP1A1/2 (which is needed for bioactivation
of this molecule) is very low in both native skin and RS models
(including Episkin and Epiderm models (van Eijl et al., 2012;
Hu et al., 2010) such that the initial activation step is not possible
or efﬁcient enough in this organ. The low CYP1A1/2 expression is
common to a number of RS skin models and to native human skin
(van Eijl et al., 2012; Götz et al., 2012a) and is not a shortcoming
of the EpiDerm model or 3D cultures in general. The lack of a
genotoxic effect by DMN is reﬂected in the cancer bioassay, in
which this compound did not cause tumours in the skin after
application to the skin of rats (although it did result in tumours
in the liver, lung and kidney) (Benemanskiı˘ and Levina, 1985).
This suggests that DMN is not bioactivated in the skin or, at least
to a sufﬁcient extent to cause MN. Based on the result observed
for 4NQO, it is recommended that a 48 h treatment is used for
general testing and a longer treatment period is used when the
outcome of the standard 48 h treatment is negative or question-
able. This practice would not cost extra time, since a negative re-
sult in the ﬁrst 48 h experiment would be repeated using the 72 h
dosing regimen instead of 48 h.
These data support the conclusion that the RSMN assay in Epi-
Derm™ is a valuable in vitromethod for genotoxicity assessment of
dermally applied chemicals. The above mentioned global valida-
tion project sponsored by Cosmetics Europe and ECVAM is contin-uing to collect data with a goal of demonstrating the strengths and
limitations of this method.5. The reconstructed skin Comet assay
As with the RSMN assay, the RS Comet project was based on
EpiDerm™ tissues. In contrast to the RSMN assay, in which the
compounds are applied for at least 48 h, this assay involves the
topical exposure to the chemicals for at least 3 h, followed by cell
isolation and assessment of DNA damage using the Comet assay.
Phase 1 studies have been completed. The method using 3D Epi-
Derm™ tissues was readily adapted and transferred to different
laboratories, showing good intra- and inter-laboratory reproduc-
ibility with two model genotoxins, methyl methane sulfonate
(MMS) and 4-NQO, in accordance with in vivo data. In Phase 2,
all laboratories tested ﬁve coded chemicals, and the reproducibility
with these chemicals was generally good (Reuss et al., 2013).
Phase 3 of this project has not yet started as we are still explor-
ing opportunities to optimize the assay. Considerable intra- and in-
ter-experimental variability was observed in some experiments, in
which the solvent control values were greater than 30% (measured
as % tail DNA). This variability was not attributable to a single fac-
tor but was thought to be a stress-induced negative impact of
transport on the quality of the tissues. The most promising way
forward along with the below described use of full thickness mod-
els is the use of ‘‘underdeveloped’’ (EPI-201) skin tissues rather
than the standard MatTek epidermal (EPI-200) tissues. The under-
developed EPI-201 tissues consist of the same normal, human-de-
rived epidermal keratinocytes and are cultured in the same
manner as standard EPI-200 tissues, but the underdeveloped tis-
sues are shipped 4 days earlier than the normal tissues (on the
week preceding the Comet assay). The EPI-201 tissues are then cul-
tured further for 4 days in the receiving laboratory to produce tis-
sues which are equivalent to the normal EPI-200 tissues. The
additional time in culture after shipping may allow the tissues to
recover from the transport-induced stress effects. The use of
underdeveloped tissues changed the rate of invalid experiments
due to a high background (>30% tail DNA in the untreated or vehi-
cle treated group) in one laboratory from 4 in 8 experiments to 1 in
9 experiments. Despite the use of these tissues lowering the back-
ground, the response of the tissues to the positive control, MMS,
was unaltered, suggesting that this modiﬁcation has not decreased
the sensitivity of the assay (Reuss et al., 2013).
The Cosmetics Europe RS Comet project ismergingwith a project
sponsored by the German Federal Ministry of Education and Re-
search (‘‘Bundesministerium für Bildung und Forschung’’, BMBF)
in order to combine efforts and more efﬁciently test the validation
chemicals in Phase 3. In the combined project wewill be investigat-
ing the usefulness of full-thickness skinmodels, aside from EPI 200/
201, since theyhavebeen shown tohave ahighermetabolic capacity
than epidermal models (Jäckh et al., 2011) and may better suited to
address the genotoxic properties of pro-mutagens.6. The ‘‘metabolism’’ project
This project investigated xenobiotic metabolising enzymes
(XMEs) innativehuman skin, RS andmonolayer cultures of skin cells
using both a proteomic approach and measurement of substrate
metabolism. The proteomic methods included immunoblotting
and a technique involving LC-MS/MSanalysis of peptides and subse-
quent software analysis (van Eijl et al., 2012). The latter method has
theadvantageof amuchhigher sensitivity than traditional immuno-
blotting techniques and it allows for a comprehensive analysis of
over 2000 XMEs. Phase 1 and 2 XME activities weremeasured using
enzyme-selective substrates for cytochrome P450s (CYPs), sul-
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(UGTs) and glutathione S-transferases (GSTs) (Götz et al., 2012a,
b,c). CYP 1–3 family proteins were not detected in native whole hu-
man skin or any of the in vitromodels tested, which reﬂects the low
mRNA expression of these CYPs reported by others (Luu-The et al.,
2009) and the lowor lackingmetabolismof CYP-selective substrates
in our studies (Götz et al., 2012a). The abundance of CYP1–3proteins
in human skin was estimated to be at levels at least 300-fold lower
than that of liver. However, there were multiple other phase 1
XME proteins that were present in signiﬁcant levels, such as alcohol
dehydrogenases, aldehyde dehydrogenases, amine oxidases and
epoxide hydrolases. GST proteins were the most abundant of the
phase 2 enzymes investigated, and were present in both native hu-
man skin and EpiDerm™ models. GST Pi was also identiﬁed as the
most abundant isoform (van Eijl et al., 2012), which correlates with
the high mRNA expression of this enzyme (Luu-The et al., 2009; Hu
et al., 2010). The GST substrate, CDNB (Sherratt and Hayes, 2002),
was metabolised at appreciable rates in whole skin (20 nmol/
min/mg), although this is still lower than that reported to be present
in human liver (van Eijl et al., 2012; Götz et al., 2012b). The potential
routes ofmetabolism in human skin and liver, based on their proteo-
mic XME proﬁles, are depicted in Fig. 3. The overall results from this
project supported the view that skin tended to be more of a detoxi-
ﬁcation than a bioactivation organ (in contrast to the liver) and that
the levels of XMEs were all generally much lower than the liver.
The XME proﬁles, using Affymetrix gene analysis, of different
donors of EpiDerm™ models has been reported to be very similar
(Hu et al., 2010) but there are no reports on how and if XMEs
change during the course of an assay. Therefore, measurement of
XMEs was adapted to determine how genotoxic compounds affect
XME activities in EpiDerm™ models used under the conditions of
the RSMN assay (Götz et al., 2012c). The genotoxins used were
BaP and cyclophosphamide, both of which require bioactivation
to their ultimate genotoxic metabolites. BaP caused a marked in-
crease in ethoxyresoruﬁn O-deethylase (reﬂecting CYP1A and
CYP1B activity, also responsible for the bioactivation of BaP Shi-
mada and Fujii-Kuriyama, 2004) activities even 24 h after the ﬁrst
dose; and these raised levels continued until the ﬁnal dose was
applied (three doses in total and 72 h of exposure). Since the
CYP1A/1B pathway was signiﬁcantly increased, this would suggestFig. 3. Potential routes of xenobiotic metabolism in skin and liver. The size of each
bioconversion indicated. (Taken from van Eijl et al., 2012 with kind permission from PLthat BaP may well cause an increase in MN formation in the Epi-
Derm™ models in the RSMN assay. This was indeed the case for
two experiments but not a third (Aardema et al., 2012), suggesting
that there is an even balance of bioactivation via CYPs and detox-
iﬁcation by GSTs (which were not induced by BaP) which can be
tipped either way in different experiments. Unlike BaP, cyclophos-
phamide did not alter any of the enzymes measured (Götz et al.,
2012c), despite their involvement in its metabolism. Unlike BaP,
cyclophosphamide was consistently positive in all experiments in
both laboratories that tested this compound (Aardema et al.,
2012). This suggests that the balance of metabolism of cyclophos-
phamide in EpiDerm™ models is towards bioactivation. Overall,
the measurement of certain XME activities in EpiDerm™ models
treated under the conditions of an endpoint assay helped in the
interpretation of the outcome.
7. Summary
The Cosmetics Europe Genotoxicity Task Force projects, which
have been running over the course of the last ﬁve years, have helped
improve predictive capacity of in vitro clastogenicity assays, and re-
sulted in an increased understanding of themethods used to predict
the in vivo genotoxic potential of dermally applied chemicals.
Important protocol modiﬁcations, namely choice of the cell type
and cytotoxicity measurement, have resulted in improved speciﬁc-
ity of the MN test such that over 60% irrelevant positive ﬁndings
could be prevented by using the optimized methods. This in itself
will lead to an increase of the predictive capacity of the initial test
battery of in vitro tests and therefore reduce the number of chemi-
cals de-selected due to misleading positives. The ‘‘3D skin model’’
project has shown that genotoxic endpoints, such as theMNandCo-
met assays, can be adapted to RS models and that the protocols
developed are robust, as demonstrated by the high degree of repro-
ducibility between andwithin laboratorieswhen coded compounds
were tested. By establishing good predictivity of the RS MN and Co-
met models, together with the conﬁrmation that the RS models mi-
mic native human skin in terms of their metabolic capacity
(demonstrated in the ‘‘Skin Metabolism project’’), our results will
support their use in follow-up tests in the assessment of the geno-
toxic hazard of cosmetic ingredients in the absence of in vivo data.arrow is proportional to the number of XMEs detected that may catalyze each
oS ONE, http://dx.doi.org/10.1371/journal.pone.0041721.g004.)
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